Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: Avelumab

First Posted Date: 2021-03-30

Last Posted Date: 2025-01-27

Lead Sponsor: Pfizer

Target Recruit Count: 599

Registration Number: NCT04822350

Locations: 🇫🇷
Centre Hospitalier de Boulogne Sur Mer, BOULOGNE SUR MER Cedex, France
🇫🇷
Hopital Louis Pradel, Bron Cedex, France
🇫🇷
Medipole de Savoie, Challes Les Eaux, France

and more 78 locations

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: talazoparib plus enzalutamide
Drug: Placebo plus enzalutamide

First Posted Date: 2021-03-29

Last Posted Date: 2025-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 599

Registration Number: NCT04821622

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Arizona Institute of Urology, PLLC, Tucson, Arizona, United States
🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States

and more 287 locations

Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years

Phase 2

Active, not recruiting

Conditions: Esophagitis

Interventions: Drug: Full dose Pantoprazole plus matching placebo
Drug: Half Dose Pantoprazole plus matching placebo

First Posted Date: 2021-03-29

Last Posted Date: 2025-06-15

Lead Sponsor: Pfizer

Target Recruit Count: 110

Registration Number: NCT04821310

Locations: 🇺🇸
Childrens Hospital of Orange County, Orange, California, United States
🇺🇸
Baptist/Wolfson's Children's Hospital, Jacksonville, Florida, United States
🇺🇸
Nemours Children's Specialty Care, Jacksonville, Florida, United States

and more 48 locations

Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

Phase 3

Completed

Conditions: Meningococcal Vaccine

Interventions: Biological: Nimenrix

First Posted Date: 2021-03-26

Last Posted Date: 2024-03-18

Lead Sponsor: Pfizer

Target Recruit Count: 149

Registration Number: NCT04819113

Locations: 🇵🇱
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o., Krakow, Poland
🇫🇮
Tampere Vaccine Research Clinic, Tampere, Pirkanmaa, Finland
🇫🇮
Jarvenpaa Vaccine Research Center, Jarvenpaa, Finland

and more 12 locations

A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Phase 4

Completed

Conditions: Transthyretin Amyloid Cardiomyopathy

Interventions: Drug: Tafamidis

First Posted Date: 2021-03-24

Last Posted Date: 2024-12-18

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT04814186

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

and more 6 locations

Drug Use Investigation of COMIRNATY Intramuscular Injection

Completed

Conditions: COVID-19

Interventions: Biological: BNT162b2

First Posted Date: 2021-03-24

Last Posted Date: 2024-11-27

Lead Sponsor: Pfizer

Target Recruit Count: 14570

Registration Number: NCT04815031

Locations: 🇯🇵
PfizerLocal Country Office, Tokyo, Japan

NOAC Portuguese Real World Study

Withdrawn

Conditions: Stroke
Systemic Embolism
Major Bleeding

Interventions: Drug: Apixaban
Drug: dabigatran
Drug: rivaroxaban
Drug: VKAs

First Posted Date: 2021-03-22

Last Posted Date: 2023-04-05

Lead Sponsor: Pfizer

Registration Number: NCT04808934

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Phase 2

Terminated

Conditions: Migraine

Interventions: Drug: BHV-3500 (zavegepant)
Drug: Placebo

First Posted Date: 2021-03-18

Last Posted Date: 2025-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 1753

Registration Number: NCT04804033

Locations: 🇺🇸
Clinical Research Philadelphia, LLC, Philadelphia, Pennsylvania, United States
🇺🇸
Meridian Clinical Research, LLC, Norfolk, Virginia, United States
🇺🇸
Clinical Investigation Specialists, Inc, Gurnee, Illinois, United States

and more 99 locations

Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

Recruiting

Conditions: ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Interventions: Drug: Vyndamax (tafamidis 61mg)

First Posted Date: 2021-03-17

Last Posted Date: 2025-01-31

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT04801329

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Phase 2

Active, not recruiting

Conditions: Lyme Borreliosis

Interventions: Biological: VLA15
Biological: Placebo

First Posted Date: 2021-03-17

Last Posted Date: 2025-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 625

Registration Number: NCT04801420

Locations: 🇺🇸
Quest Diagnostics, Marlborough, Massachusetts, United States
🇺🇸
Pfizer Vaccine Research and Development, Pearl River, New York, United States
🇩🇪
Synevo Studien Service Labor GmbH c/o Institut für Medizinische Diagnostik, Berlin, Germany

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy